Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 55
- Profitability 25
- Business Quality 50
- Balance Sheet 55
- Cash Flow 40
Why this rating?
Health 33/100 — Avoid
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Amylyx Pharmaceuticals, Inc. (AMLX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Amylyx Pharmaceuticals, Inc. 33/100 (Avoid) due to solid business quality.
Investment profile
- Quality Moderate
- Balance Sheet Unknown
Financial highlights
Valuation
- Forward P/E -29.34
Profitability
- Gross Margin 0.0%
- Operating Margin 0.0%
- Net Margin 0.0%
- ROE -74.7%
Financial strength
- Cash $250.76M
- Debt $5.25M
- Net Cash $245.50M
- Free Cash Flow $-123.48M
- Current Ratio 12.12
Similar companies
Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- BioCryst Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic BCRX$9.06 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Zoetis Inc. Drug Manufacturers - Specialty & Generic ZTS$73.56 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Neurocrine Biosciences, Inc. Drug Manufacturers - Specialty & Generic NBIX$155.13 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Good Entry Good EntryA usable setup — not as clean as Strong Entry, but timing is not mixed or weak.
- Lantheus Holdings, Inc. Drug Manufacturers - Specialty & Generic LNTH$100.44 70 Health 70 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Trulieve Cannabis Corp. Drug Manufacturers - Specialty & Generic TRLV$12.43 64 Health 64 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Alkermes plc Drug Manufacturers - Specialty & Generic ALKS$45.49 62 Health 62 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Hims & Hers Health, Inc. Drug Manufacturers - Specialty & Generic HIMS$28.17 61 Health 61 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Supernus Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic SUPN$42.43 60 Health 60 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Amylyx Pharmaceuticals, Inc. (AMLX).